Adding Rituximab to Chemo Ups Event-Free Survival in ALL

Share this content:
Adding Rituximab to Chemo Ups Event-Free Survival in ALL
Adding Rituximab to Chemo Ups Event-Free Survival in ALL

MONDAY, Sept. 19, 2016 (HealthDay News) -- For young adults with acute lymphoblastic leukemia (ALL), adding rituximab to chemotherapy is associated with increased event-free survival, according to a study published in the Sept. 15 issue of the New England Journal of Medicine.

Sébastien Maury, M.D., Ph.D., from the Hôpital Henri Mondor in Paris, and colleagues randomized 209 adults aged 18 to 59 years with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to chemotherapy with (105 patients) or without rituximab (104 patients). Rituximab was given during all treatment phases (16 to 18 infusions).

The researchers found that event-free survival was longer in the rituximab group than the control group (hazard ratio, 0.66; P = 0.04) after a median follow-up of 30 months, with estimated two-year event-free survival rates of 65 and 52 percent, respectively. In multivariate analysis, treatment with rituximab remained associated with longer event-free survival. There was no significant between-group difference noted in the overall incidence rate of severe adverse events; the rituximab group had fewer allergic reactions to asparaginase.

"Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Genentech, the manufacturer of rituximab.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ultraviolet B Radiation Exposure Tied to Decreased Risk of Myopia

Ultraviolet B Radiation Exposure Tied to Decreased Risk ...

More exposure to sun's UVB rays between ages 14 and 29 linked to lower risk

Vitamin D in Pregnancy Might Help Prevent MS in Offspring

Vitamin D in Pregnancy Might Help Prevent MS ...

Infants born with low levels of vitamin D may be more likely to develop multiple sclerosis later in life

Dabigatran May Be Better Than Warfarin After Bleeding Episode

Dabigatran May Be Better Than Warfarin After Bleeding ...

Resuming any anticoagulant found safer than stopping the drugs in these cases

is free, fast, and customized just for you!

Already a member?

Sign In Now »